Grants for Unrestricted - Federal

This grant provides funding to the Northern New England Passenger Rail Authority to improve collaboration and support for intercity passenger rail services among state partners, Amtrak, and federal agencies.

This funding opportunity provides substantial financial support to national organizations for expanding mentoring services aimed at helping at-risk youth, particularly those from underserved communities, to prevent delinquency and promote positive development.

The FY24 ALSRP Therapeutic Development Award supports research ranging from preclinical validation of therapeutic leads through Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited ALS experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints, and pathophysiology.Applications supported by this award must begin with lead compounds in hand and must include proof-of-concept efficacy data in at least one preclinical model system of ALS, including whole animal and cellular model systems.Examples of activities that will be supported by this award include:Confirmation of candidate therapeutics obtained from screening or by other means, including optimization of potency and pharmacological properties and testing of derivatives and sister compounds.Validation of pilot efficacy studies (such as from an ALSRP Therapeutic Idea Award [TIA]), including the use of additional ALS model systems and/or replicating preliminary data with more time points or additional doses.ND-enabling studies to include: compound characterization; absorption, distribution, metabolism, and excretion (ADME) studies; studies on formulation and stability leading to Good Manufacturing Practice production methods; dose/response and toxicology studies in relevant model systems.Applicants seeking support for basic research focused on ALS drug discovery are encouraged to apply for the FY24 ALSRP TIA (Funding Opportunity Number HT942524 ALSRP TIA), which does not require preliminary data (https://cdmrp.health.mil/funding/alsrp).Mechanism-specific, predictive/cohort-selective, target engagement, and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY24 ALSRP Therapeutic Development Award. If biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported. Applicants seeking support for biomarker development independent of therapeutic development are encouraged to apply for the FY24 ALSRP Clinical Outcomes and Biomarkers Award (Funding Opportunity Number HT942524ALSRPCOBA).

The NFRP Synergistic Idea Award supports new ideas that represent synergistic approaches to NF research involving two or three Principal Investigators (PIs). These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in NF research. This award is designed to support both new and pre-existing partnerships and encourages participation of PIs from other research fields. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.

Subject: Jordan RFI/SSN: Prevent, Detect, Respond - Primary Health Care (PDR-PHC) ActivityThe United States Agency for International Development in Jordan (USAID/Jordan) Mission isgathering information for a potential Global Health Security (GHS) activity. The Activity willinclude a package of interventions to strengthen biosecurity and safety, address antimicrobialresistance (AMR), and prevent and respond to emerging threats through building One Healthcapacities that incorporate linkages between human, animal, and environmental health.Through focusing its interventions at the primary healthcare level, the activity will strengthenhealth provider practices, health system preparedness, multi-sectoral coordination, andsurveillance capabilities to 1) prevent avoidable disease outbreaks, 2) detect threats early, 3)respond rapidly and effectively when outbreaks occur.This RFI/SSN seeks responses to the below inquiries as well as information on the availability,interest, and diverse capacities of GHS-focused entities to carry out such tasks and theirability to collaborate with local entities.This RFI/SSN is issued solely for information and planning purposes. It is NOT a Request forProposal (RFP), nor Notice of Funding Opportunity (NOFO), and in no way obligates the U.S.Government to issue an RFP/NOFO and/or award a contract/grant or pay for any informationsubmitted as a result of this request. If a solicitation is issued, all necessary information willbe supplied at the time it is posted at grants.gov or sam.gov.

The "Climate Resilient Cities Activities in India Addendum to the Locally Led Development Annual Program Statement (APS) No. 7200AA24APS00006" grant is a special call by USAID/India for local entities to submit concepts for climate resilient projects in at least two cities among Mumbai, Bengaluru, Bhiwadi, and Guwahati, with a total funding of $4 million for two or more awards, each not exceeding $2 million, for an initial period of three years.

This funding opportunity provides financial support for projects that promote the development and deployment of floating offshore wind technologies, enhance environmental monitoring, and foster education and research in the offshore wind industry across the United States.

The NFRP Exploration - Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research. Studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is not required.

This program provides funding to a wide range of applicants, including universities, companies, and non-profits, to develop innovative technologies for faster and more accurate mineral resource characterization, particularly for rare earth elements and critical minerals essential for energy production.

This grant provides funding to establish a council and leadership academy for former unaccompanied children and their sponsors, focusing on empowering their voices, sharing best practices for their support, and enhancing their community leadership skills.

This initiative seeks input from stakeholders to improve strategies for developing advanced materials and manufacturing processes that can withstand extreme conditions, particularly for applications in energy production and sustainability.

The FY24 KCRP Postdoctoral and Clinical Fellowship Award supports recent doctoral or medical school graduates in pursuit of innovative, high-impact kidney cancer research during their postdoctoral and/or clinical fellowship and allows them to obtain the necessary experience for an independent career as a leader in kidney cancer research. Applicants must demonstrate that the proposed research has high potential to lead to, or make, significant advancements in kidney cancer research and/or patient care. Applicants for this award must also exhibit a strong desire to pursue a career in kidney cancer research, with clear evidence for a researcher development plan that will lead to a successful independent career in kidney cancer. The critical components of this award mechanism are: Impact: Research supported by the FY24 KCRP Postdoctoral and Clinical Fellowship Award will have the potential for a major impact and accelerate progress toward ending kidney cancer. The impact may be short term or long term, but must move beyond an incremental advance. Applications are expected to identify the kidney cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Strategy: The research proposed as part of the Postdoctoral and Clinical Fellowship Award must have high potential to lead to or make breakthroughs in kidney cancer. The scope of the research may include innovative, high-risk/high-reward research in the early stages of idea development or research already supported by preliminary data with the potential to make significant advancements toward clinical translation. The research strategy should demonstrate sound rationale, logical reasoning, and, if available, preliminary data. The proposed research should show evidence of rigorous experimental design, sufficient experimental details, appropriate controls, a statistical plan, and consideration of pitfalls and alternatives. Principal Investigator (PI): Under this award mechanism, the postdoctoral or clinical fellow is considered the PI and, as such, is expected to write the project narrative, researcher development plan, and other application components, with appropriate guidance from the mentor. While the PI is not required to have previous experience in kidney cancer research, the proposed project and researcher development plan must focus on kidney cancer. Applications must emphasize the PIs potential for success in becoming an independent kidney cancer researcher based on their qualifications, achievements/honors (including first-author publications and funding), and letters of recommendation. Mentor: The mentor (or co-mentor, if applicable) must possess the appropriate experience in kidney cancer research and/or patient care, to include recent publications and a record of active funding, and clearly demonstrate a commitment to guiding the PIs research and development as a researcher. If the mentor is not an experienced kidney cancer researcher, then formal co mentorship by an established kidney cancer researcher is required. The application must include information about the mentors experience in conducting innovative research and how they intend to support the PIs endeavors in kidney cancer. Mentorship by an investigator without an established record of mentoring pre- and/or postdoctoral trainees may be offset by the overall strength of the researcher development plan. Researcher Development Plan: Applications must provide details on the suitability of the PIs overall researcher development plan for attaining the goals of this award mechanism. Applications must elaborate on the qualities of the research environment in which the candidate will work, provide details on the individualized kidney cancer-focused researcher development plan, and describe how it will facilitate the PIs career development as an independent, innovative kidney cancer researcher. A multidisciplinary research approach to kidney cancer is highly encouraged, but not required; however, if there are multidisciplinary aspects, they should be clearly outlined in the application. Organizational-Level Emphasis: The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/or focus areas described in Section II.A.1 and Section II.A.2. Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health. Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities. Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this program announcement. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. The funding instrument for awards made under the program announcement will be grants (31 USC 6304). The anticipated direct costs budgeted for the entire period of performance for an FY24 KCRP Postdoctoral and Clinical Fellowship Award should not exceed $195,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $2.18M to fund approximately seven Postdoctoral and Clinical Fellowship Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports researchers investigating health issues related to military toxic exposures, providing financial resources for studies ranging from basic research to clinical trials.

This funding opportunity is for research institutions and organizations that are partners in the Great Basin Cooperative Ecosystem Studies Unit, aimed at developing advanced hydrodynamic models to study water flow between Bear River Bay and Gilbert Bay in the Great Salt Lake.

The Energy Storage Pilot Demonstrations program, managed by the Office of Clean Energy Demonstrations (OCED), supports pilot-scale demonstrations for non-lithium, long-duration energy storage solutions. The program aims to advance technical maturity, reduce uncertainty in cost and performance, generate operational datasets, and increase investor and end-user confidence. The total DOE funding available is up to $100 million, with project funding ranging from $5 million to $20 million DOE share, requiring a minimum of 50 percent non-Federal cost share. Projects must demonstrate long-duration (10 hour) discharge capabilities and have a clear path to commercialization.

The "DoD Multiple Sclerosis, Investigator-Initiated Research Award" is a grant that supports high-quality research projects aimed at improving understanding, patient care, and quality of life for those with Multiple Sclerosis, and encourages applications from both established and early-career investigators, with a focus on projects that can provide relevant preliminary or published data.

Grant Title: Request for Information to Participate in Customized Locally Focused Workshop Series on How to Work with USAID. This grant aims to gather information from local Pakistani organizations to design workshops that will guide them on collaborating with USAID, enhance their capacity to lead in USAID's development process, and prepare them for future co-creation opportunities.

This funding opportunity supports organizations working to improve sustainable and resilient port infrastructure in South Asia, enhancing regional economic connectivity and maritime trade efficiency.

This funding opportunity provides financial support for CESU partners to develop and improve a flood disturbance model that simulates forest dynamics in floodplain ecosystems along the Upper Mississippi River.

This initiative seeks to engage organizations with expertise in monitoring, evaluation, and learning to support USAID's development efforts in Haiti across various sectors, enhancing data-driven decision-making and local capacity-building.